Dialog Box

Skin Health Institute

Clinical Trials - For Clinicians


To receive weekly updates on our currently recruiting trials, fill out the following form. 

These research study descriptions are intended for clinicians only. Information for potential study participants can be found here

If you would like to learn more about any of the studies currently being conducted at the Skin Health Institute, please contact the nominated study coordinator.

If you have any general questions regarding the clinical trials conducted at the Institute, please feel free to contact the Clinical Trials Department at trials@skinhealthinstitute.org.au or by phone on (03) 9623 9439.

Melanoma Research Study

Phase III Hidradenitis Suppurativa Research Study

Melanoma Research study


Melanoma surveillance photography (MSP)

What is the IMAGE study?

The IMAGE Study (Melanoma surveillance photography to improve early detection of melanoma) tests whether an advanced medical imaging technology called Melanoma Surveillance Photography (MSP), in addition to usual care, helps to improve outcomes compared to usual care alone.

What is MSP?
What is involved in melanoma surveillance photography (MSP)?
MSP combines 2D or 3D total body photography (images of the whole skin surface) with digital dermoscopy (close-up photos of individual skin lesions) to closely monitor lesions and is performed at set intervals – annually in the IMAGE study.

New technology is available that enables rapid, radiation-free total body imaging. These images can be reviewed by your usual doctor to monitor the appearance of skin lesions over time and may help to improve detection of malignant lesions – and to better differentiate malignant from benign lesions.

Eligibility Criteria

Who is eligible to participate?
The IMAGE study is currently recruiting patients with a diagnosis of melanoma within the last 6 months (186 days). Your doctor will be discussing the IMAGE study with you because you have recently been diagnosed with your first melanoma and you may be eligible to participate - if other criteria are also met.

If you are:

  • Aged 18 years or older at date of diagnosis of your first melanoma.
  • Able to provide consent, complete questionnaires, and attend a local study site for MSP.
  • Able to be referred for total body photography (you will need to undress to underwear and stand for imaging)
  • Have “some” or “many” moles; and
  • Currently living in Australia and have no plans to move overseas within the next 3 years.

you may be eligible to participate in the IMAGE study.

There are certain types of melanomas that will mean you are not eligible, even if all criteria above have been met. Your doctor will discuss whether they are relevant for your circumstances. This sheet provides a brief outline of the study but not all information participants will need to consider when thinking about joining the study.

For more detailed information about this study, download the Image Trial Clinicians Information and the Image Trial Patient Referral.

Back to top

Phase iii Hidradenitis Suppurativa Research Study


A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa.

Background and Rationale

Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, debilitating skin disease that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body. The affected areas are: inguinal, axillary, perineal and perianal as well as the submammary and/or intermammary fold in women, buttocks, mons pubis, scalp, area behind the ears and eyelids.

Bimekizumab is an engineered, humanized full-length mAb of IgG1 subclass being developed for the treatment of patients with inflammatory diseases such as PSO, psoriatic arthritis, axial spondyloarthritis, and HS. Bimekizumab has a high affinity for human IL-17A and human IL-17F, and selectively and potently inhibits the activity of both isoforms in vitro.


The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).

Back to top